

## Bio-Rad (BIO)

**\$308.13** (Stock Price as of 12/12/2025)

Price Target (6-12 Months): **\$334.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 08/26/25)

Prior Recommendation: Underperform

Short Term: 1-3 Months

**Zacks Rank: (1-5)**

**4-Sell**

Zacks Style Scores:

VGM: B

Value: D

Growth: B

Momentum: A

## Summary

Bio-Rad is gaining momentum in the ddPCR space, with the acquisition of Stilla Technologies further strengthening the portfolio. Drawing on its established reputation as a leading blood screening systems provider, the IH-500 blood typing system is considered a gold standard in immunohematology labs, offering the highest level of automation. The company also has significant operations internationally. Going by our model, total revenues are expected to improve 0.6% and 2.1%, respectively, in 2025 and 2026. Solid financial stability is another advantage. Meanwhile, Bio-Rad is facing significant pressure due to downturns in the biopharma, biotech and academic markets. Uncertainty due to tariffs and other challenging global economic conditions adds to the concerns. A fierce competitive landscape can also bring operational risks.

## Data Overview

52 Week High-Low	\$373.69 - \$211.43
20 Day Average Volume (sh)	158,390
Market Cap	\$8.3 B
YTD Price Change	-6.2%
Beta	1.18
Dividend / Div Yld	\$0.00 / 0.0%
Industry	<a href="#">Medical - Products</a>
Zacks Industry Rank	Bottom 32% (165 out of 243)


Last EPS Surprise	-1.7%
Last Sales Surprise	0.2%
EPS F1 Est- 4 week change	-0.4%
Expected Report Date	02/12/2026
Earnings ESP	0.0%

P/E TTM	29.9
P/E F1	30.9
PEG F1	128.6
P/S TTM	3.3

## Price, Consensus & Surprise<sup>(1)</sup>



## Sales and EPS Growth Rates (Y/Y %)<sup>(2)</sup>



## Sales Estimates (millions of \$)<sup>(2)</sup>

	Q1	Q2	Q3	Q4	Annual*
2026	605 E	636 E	688 E	711 E	2,640 E
2025	585 A	652 A	653 A	693 E	2,583 E
2024	611 A	638 A	650 A	668 A	2,567 A

## EPS Estimates<sup>(2)</sup>

	Q1	Q2	Q3	Q4	Annual*
2026	2.79 E	2.35 E	2.61 E	2.60 E	10.36 E
2025	2.54 A	2.61 A	2.26 A	2.57 E	9.98 E
2024	2.29 A	3.11 A	2.01 A	2.90 A	10.31 A

\*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 12/12/2025.

(2) The report's text, the analyst-provided estimates, and the price target are as of 12/08/2025.

## Overview


Hercules, CA-headquartered Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components.

Bio-Rad has extensive and direct distribution channels in more than 36 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

The company operates through two industry segments, which combined offer over 12,000 different products and services. The details are as follows:

**Life Science (40.1% of total revenues in 2024, down 12.8% from 2023):** This segment designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. The company believes Life Science Segment represents a global market opportunity of approximately \$9 billion annually.

**Clinical Diagnostics (44.2%, up 3.3%):** The segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rad also supplies several thousand products spanning more than 300 clinical diagnostic tests to the in vitro diagnostics (IVD) test market. The Clinical Diagnostics segment presents an annual global market opportunity of roughly \$16 billion.



As of 12/08/2025



As of 12/12/2025

## Reasons To Buy:

▲ **Digital PCR Business Backs Bio-Rad's Growth:** Bio-Rad is consistently developing its foothold in the rapidly growing digital PCR space. Last year, the company made investments in companies developing potentially best-in-class diagnostics using its ddPCR technology, such as Geneoscopy and OncoCyte. In 2025, it introduced key assay expansions, including enhancements to the VeriCheck assays for cell and gene therapy, showing a strong correlation between circulating tumor DNA and treatment outcomes in lung cancer. Additionally, the acquisition of Stilla Technologies further strengthened its ddPCR offering and facilitate entry into new molecular testing markets. Coinciding with this, Bio-Rad launched the rebranded QX700 Series ddPCR instruments, which, together with QX Continuum, enhance the ddPCR portfolio for customers requiring a simplified workflow and flexibility at various budget levels.

Bio-Rad's Clinical Diagnostics arm continues to gain momentum. The company's focus on geographic expansion is also encouraging.

In the third quarter of 2025, Bio-Rad advanced its ddPCR strategy, completing global sales training of the new QX platforms and actively engaging customers. Also, Gencurix made Bio-Rad the exclusive distributor of their Droplex oncology testing kits across Europe. Bio-Rad also expanded its partnership with Biodesix to improve access to key biomarker testing for advanced breast cancer.

▲ **Clinical Diagnostics Continues to Gain Momentum:** The business has now returned to its normalized growth rate post-pandemic, maintaining strong market positions globally for its platforms. Built on its long-standing reputation as a leading blood screening systems provider, Bio-Rad's IH-500 blood typing system is considered a gold standard in immunohematology labs, offering the highest level of automation. The company introduced the IH-500 NEXT System in 2023, a fully automated system for ID cards to meet emerging demands and challenges in laboratory and health environments. Bio-Rad continues to invest in supporting the growth of this segment while building a position in the new molecular diagnostics segment.

In the third quarter of 2025, Clinical Diagnostics sales edged up 0.6% year over year. Performance remained stable across the product areas, with the exception of reimbursement rate headwind in China, which is expected to annualize in the fourth quarter. Our model projects Clinical Diagnostics' sales to improve 0.7% in 2025, followed by a 1.6% increase in 2026.

▲ **Solid Prospects in the Blood Typing Market:** Bio-Rad offers a broad range of platforms, reagents, data management, and connectivity solutions to cater to various blood typing demands, offering efficient and reliable results for blood grouping, phenotyping, crossmatching, antibody screening and identification, direct antiglobulin tests, and single antigen typing. The company has also been actively expanding its portfolio for the blood typing market. The company currently offers products like IH-500 and IH-1000. Per a report by Grand View Research, the global blood group typing market size was valued at \$2.12 billion in 2024 and is expected to witness a CAGR of 8.6% by 2030. Taking this into account, we view the developmental steps undertaken by the company as progressive and strategically aligned.

▲ **Focus on International Markets:** Bio-Rad conducts significant international operations, having direct distribution channels in more than 36 countries outside the United States. So far this year, the company has generated nearly 59% of its net revenues from international locations, with Europe being the largest international region. Despite the soft market conditions in APAC regions for the Life Science business, the company remains optimistic about the continued gradual improvement into 2025.

Further, the lackluster business scenario in the key European markets, primarily due to an unfavorable funding environment in Germany and in the United Kingdom, is expected to be gradually offset by a more modest improvement in funding outlooks in France and some other European countries. Per our model, EMEA 2025 sales are expected to increase 3.1%.

▲ **Strong Solvency and Balance Sheet:** Bio-Rad exited the third quarter of 2025 with cash and cash equivalents (including short-term investments) of \$1.42 billion, and \$1 million in short-term debt. Total debt (including current maturities) at the end of the second quarter was \$1.20 billion, in line with the previous quarter's level. The reported figure was lower than the corresponding cash and cash equivalent and investment levels. This indicates a strong solvency position for the company.

## Reasons To Sell:

- ▼ **Weakness in End Markets:** The company continues to be negatively impacted by the ongoing challenges impacting the biopharma market and small biotech companies. In early 2025, the U.S. government proposed reductions of federal funding to some institutions and companies that are part of Bio-Rad's customer base. Although there have been signals of improvement, customers are still cautious about the funding environment and conservative in allocating capital. Third-quarter 2025 core Life Sciences revenues decreased 7.8% on a currency-neutral basis, as a result of this, along with tough comparison due to large one-time orders in the year-ago period. Added to this, large pharmaceutical companies are implementing cost-saving measures through corporate restructuring and R&D reprioritization. Despite the possibility of a flat NIH budget for 2026, the pace of recovery in the academic segment is expected to remain slow as researchers will take time to regain confidence in the longer-term funding outlook.
- ▼ **Macroeconomic Concerns:** In recent years, the company's performance has been affected by challenging economic conditions, including elevated raw material costs from inflationary pressures and geopolitical turmoil. Moderating economic growth and changing government policies in China are likely to continue affecting Bio-Rad's commercial opportunities in the country and also hurt the demand for its Clinical Diagnostics products. Additionally, it continues to assess the uncertain tariff situation and its impacts on the business as events continue to unfold. Any further increase in tariffs or other trade barriers could adversely impact Bio-Rad's profitability and competitive standing. Besides, economic downturns can lead to a decrease in demand for its products, increased competition, downward pressure on prices for its products, and longer sales cycles.
- ▼ **Tough Competitive Pressure:** Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit its ability to switch to strategies like price increases and other drivers of cost increases. Further, the extension of the public tender commitments to multiple years by the government, resulting in a reduced number of annual tenders, has led to aggressive tender pricing by Bio-Rad's competitors. Thus, Bio-Rad faces pricing pressure resulting from increased competition, which makes it difficult for the company to manage its operational, financial, and business conditions efficiently.
- ▼ **Exposure to Foreign Currency:** Internationally, Bio-Rad's sales are primarily denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts the company's consolidated net sales expressed in U.S. dollars. Further, the volatility of other currencies may adversely affect the company's operations outside the United States and increase its internal costs to hedge against currency fluctuations.
- ▼ **Reduced Reimbursement Rates:** Bio-Rad's Clinical Diagnostics business is exposed to changing reimbursement rates for clinical tests from third-party payors like Medicare and Medicaid in the United States. Payment for several diagnostic tests furnished to Medicare fee-for-service beneficiaries is dependent on the Medicare Clinical Laboratory Fee Schedule (CLFS) in the United States. Further, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle-Class Tax Relief and Job Creation Act of 2012, has lowered payments for clinical laboratory services paid under the CLFS. Additionally, the Protecting Access to Medicare Act of 2014 (PAMA) rule has led to lower reimbursement rates and modes of payment for clinical laboratory services by Medicare. In the third quarter of 2025, Clinical Diagnostics sales decreased 1.8% on a currency-neutral basis because of a lower reimbursement rate for diabetes testing in China.
- ▼ **Difficult Pricing Scenario:** The healthcare industry continually strives to cut down its expenditures by undergoing significant changes. The trend toward managed care, the healthcare reform of the delivery system in the United States, and efforts to reform in Europe have resulted in increased pressure on healthcare providers and other participants in the said industry to reduce selling prices. Additionally, consolidations among healthcare providers and among the industry participants have resulted in fewer and more powerful groups, whose purchasing power gives them cost containment leverage. These industry trends and competitive forces place constraints on the company's overall pricing levels and could have a material adverse effect on the gross margins for products that it sells in the clinical diagnostic markets.

BioPharma's softness, macroeconomic conditions in China, competitive pressures and adverse currency impacts pose a threat to Bio-Rad's business performance.

## Last Earnings Report

### Bio-Rad Misses Q3 Earnings Estimates

Bio-Rad Laboratories, Inc. posted third-quarter 2025 adjusted earnings per share of \$2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from the prior-year quarter's level.

The quarter's adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.

The company's GAAP loss was \$12.70 per share compared to the earnings of \$23.34 a year ago.

### BIO's Q3 Revenues

Revenues of \$653 million topped the Zacks Consensus Estimate by 0.24%. The figure also edged up 0.5% year over year (down 1.7% at constant exchange rate or CER).

Following the earnings announcement, Bio-Rad shares dropped 2.96% in yesterday's after-market trading.

### BIO's Segmental Analysis

Sales in the Life Science segment totaled \$261.8 million, up 0.3% year over year (down 1.5% at CER). The currency-neutral year-over-year sales decline was due to a constrained academic research and biotech funding environment.

Net sales in the Clinical Diagnostics segment were \$391.2 million, up 0.6% on a year-over-year basis (down 1.8% at CER). The currency-neutral year-over-year sales decrease was primarily due to lower reimbursement rates for diabetes testing in China.

### BIO's Margin Performance

In the quarter under review, Bio-Rad's gross profit declined 3.5% to \$343.4 million. The gross margin contracted 219 basis points (bps) to 52.6%.

Operating expenses amounted to \$278.1 million, down 4.6% year over year. The operating profit totaled \$65.3 million, up 1.2% from the prior-year level. The operating margin expanded 7 bps to 10%.

### BIO's Financial Update

Bio-Rad exited the third quarter of 2025 with cash and cash equivalents (including short-term investments) of \$1.42 billion compared with \$1.37 billion at the second-quarter end.

Total debt (including current maturities) at the end of 2024 was \$1.20 billion, which remained flat on a sequential basis.

Net cash flow from operating activities totaled \$367.3 million compared with the year-ago figure of \$331 million.

### Bio-Rad's 2025 Guidance

Bio-Rad reiterated its financial guidance for full-year 2025, with adjusted, currency-neutral revenue growth of approximately 0-1%. The Zacks Consensus Estimate for the company's revenues is pegged at \$2.58 billion, implying a 0.6% increase from the 2024 reported figure.

The adjusted operating margin for the full year is projected to be between 12% and 13%.

**FY Quarter Ending** **12/31/2024**

Earnings Reporting Date	Oct 29, 2025
Sales Surprise	0.24%
EPS Surprise	-1.74%
Quarterly EPS	2.26
Annual EPS (TTM)	10.31

## Valuation

Bio-Rad shares are down 3.3% in the year-to-date period and down 8% in the trailing 12-month period. Stocks in the Zacks sub-industry are up 3.2% while the Zacks Medical sector is up 6% in the year-to-date period. Over the past year, the Zacks sub-industry is down 0.9% and sector is down 1.6%.

The S&P 500 index is up 19.2% in the year-to-date period and up 16.3% in the past year.

The stock is currently trading at 30.7X Forward 12-months earnings, which compares to 20.1X for the Zacks sub-industry, 20.8X for the Zacks sector and 23.6X for the S&P 500 index.

Over the past five years, the stock has traded as high as 64.3X and as low as 18.9X, with a 5-year median 29.6X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$334 price target reflects 32.3X forward 12-months earnings.

The table below shows summary valuation data for BIO.

Valuation Multiples - BIO					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	30.74	20.14	20.84	23.59
	5-Year High	64.34	27.41	23.62	23.78
	5-Year Low	18.85	17.79	17.88	15.73
	5-Year Median	29.59	21.92	20.69	21.21
P/S F12M	Current	3.25	2.86	2.15	5.33
	5-Year High	8.81	4.49	3.41	5.50
	5-Year Low	2.27	2.55	2.01	3.83
	5-Year Median	3.83	3.20	2.64	5.05
P/B TTM	Current	1.27	2.87	3.95	8.56
	5-Year High	2.12	4.49	6.08	9.16
	5-Year Low	0.85	2.44	3.57	6.60
	5-Year Median	1.35	3.14	4.53	8.04

As of 12/05/2025

Source: Zacks Investment Research



## Industry Analysis<sup>(1)</sup> Zacks Industry Rank: Bottom 32% (165 out of 243)



## Top Peers<sup>(1)</sup>

Company (Ticker)	Rec	Rank
National Vision Hold...(EYE)	Neutral	3
GN Store Nord (GNNDY)	Neutral	4
ICU Medical, Inc. (ICUI)	Neutral	3
Envista Holdings Cor...(NVST)	Neutral	3
AdaptHealth Corp. (AHCO)	Underperform	5
QuidelOrtho Corporat...(QDEL)	Underperform	4
Shandong Weigao Medi...(SHWGF)	NA	
Demant A/S Unsponsor...(WILYY)	NA	

## Industry Comparison<sup>(1)</sup> Industry: Medical - Products

	BIO	X Industry	S&P 500	AHCO	GNNDY	NVST
Zacks Recommendation (Long Term)	Neutral	-	-	Underperform	Neutral	Neutral
Zacks Rank (Short Term)	4	-	-	5	4	3
VGM Score	B	-	-	A	C	B
Market Cap	8.31 B	257.34 M	39.38 B	1.41 B	0.00 M	3.61 B
# of Analysts	1	3	22	3	1	7
Dividend Yield	0.00%	0.00%	1.41%	0.00%	0.00%	0.00%
Value Score	D	-	-	A	C	B
Cash/Price	0.17	0.16	0.04	0.06	NA	0.31
EV/EBITDA	-3.53	4.10	14.60	4.78	NA	-4.46
PEG Ratio	127.00	1.92	2.23	1.27	NA	1.08
Price/Book (P/B)	1.23	1.69	3.35	0.87	1.77	1.17
Price/Cash Flow (P/CF)	29.65	10.46	15.20	2.74	7.84	13.23
P/E (F1)	30.48	19.30	19.78	13.99	16.22	19.30
Price/Sales (P/S)	3.25	1.64	3.06	0.43	NA	1.38
Earnings Yield	3.24%	0.19%	4.99%	7.12%	6.17%	5.19%
Debt/Equity	0.18	0.16	0.57	1.09	0.81	0.47
Cash Flow (\$/share)	10.39	0.02	8.99	3.79	6.82	1.66
Growth Score	B	-	-	B	B	C
Hist. EPS Growth (3-5 yrs)	-8.46%	-0.52%	8.16%	17.85%	-17.66%	-15.52%
Proj. EPS Growth (F1/F0)	-3.20%	9.66%	8.57%	-22.92%	12.24%	56.16%
Curr. Cash Flow Growth	-15.68%	3.38%	6.75%	-63.28%	-11.68%	-34.49%
Hist. Cash Flow Growth (3-5 yrs)	6.44%	8.49%	7.43%	48.58%	-1.96%	-9.00%
Current Ratio	5.44	2.33	1.19	1.08	1.14	2.37
Debt/Capital	15.13%	22.38%	38.01%	52.09%	44.89%	31.88%
Net Margin	-26.43%	-7.30%	12.78%	2.53%	4.05%	0.58%
Return on Equity	4.19%	-5.57%	17.00%	4.85%	6.49%	5.90%
Sales/Assets	0.26	0.57	0.53	0.74	0.57	0.47
Proj. Sales Growth (F1/F0)	0.60%	0.00%	5.77%	-1.00%	1.60%	5.30%
Momentum Score	A	-	-	B	D	C
Daily Price Chg	-1.86%	0.00%	-1.07%	1.46%	9.54%	-0.77%
1 Week Price Chg	-3.01%	0.00%	-0.63%	10.40%	11.83%	8.60%
4 Week Price Chg	-1.60%	3.19%	1.39%	13.17%	4.53%	13.25%
12 Week Price Chg	8.47%	-4.74%	2.45%	16.99%	-1.71%	4.97%
52 Week Price Chg	-8.37%	-8.46%	12.83%	8.90%	-8.06%	12.84%
20 Day Average Volume	158,390	185,433	2,728,366	1,021,872	405	1,909,416
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-0.40%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 12 week change	3.05%	0.47%	0.69%	-23.93%	-5.31%	2.57%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.00%	0.00%	NA	0.00%

## Analyst Earnings Model<sup>(2)</sup>

### Bio-Rad Laboratories, Inc. (BIO)

In \$MM, except per share data

	2018A	2019A	2020A	2021A	2022A	2023A	2024A	2025E				2026E				2027E		
	FY	FY	FY	FY	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY Ends December 31st	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	31-Mar-25	30-Jun-25	30-Sept-25	31-Dec-25	Dec-25	31-Mar-26	30-Jun-26	30-Sept-26	31-Dec-26	Dec-26	Dec-27
Income Statement																		
Total Revenue, Non-GAAP	\$2,289.4	\$2,311.7	\$2,513.7	\$2,890.7	\$2,802.2	\$2,671.3	\$2,566.5	\$585.4	\$651.6	\$653.0	\$693.1	\$2,583.1	\$605.0	\$636.2	\$687.7	\$711.0	\$2,639.9	\$2,367.3
Total Revenue, GAAP	\$2,289.4	\$2,311.7	\$2,545.6	\$2,922.5	\$2,802.2	\$2,671.3	\$2,566.5	\$585.4	\$651.6	\$653.0	\$693.1	\$2,583.1	\$605.0	\$636.2	\$687.7	\$711.0	\$2,639.9	\$2,367.3
COGS, Non-GAAP	\$1,040.7	\$1,040.2	\$1,082.7	\$1,236.9	\$1,216.2	\$1,222.9	\$1,154.9	\$270.4	\$301.7	\$303.6	\$320.2	\$1,195.9	\$253.2	\$279.6	\$315.5	\$335.0	\$1,183.3	\$1,033.8
COGS, GAAP	\$1,066.3	\$1,054.6	\$1,107.7	\$1,284.4	\$1,234.9	\$1,244.3	\$1,187.6	\$279.4	\$306.3	\$309.6	\$336.8	\$1,232.1	\$271.7	\$281.6	\$324.1	\$346.4	\$1,223.8	\$1,109.7
Gross Profit, Non-GAAP	\$1,248.7	\$1,271.4	\$1,431.0	\$1,653.8	\$1,586.1	\$1,448.3	\$1,411.6	\$315.0	\$349.9	\$349.4	\$372.9	\$1,387.2	\$351.8	\$356.6	\$372.2	\$376.0	\$1,456.7	\$1,333.5
Gross Profit, GAAP	\$1,223.2	\$1,257.0	\$1,437.8	\$1,638.1	\$1,567.3	\$1,426.9	\$1,378.9	\$306.0	\$345.3	\$343.4	\$356.3	\$1,351.0	\$333.3	\$354.7	\$363.6	\$364.6	\$1,416.2	\$1,257.6
Selling, General & Administrative, Non-GAAP	\$806.4	\$796.2	\$776.5	\$824.0	\$805.4	\$814.6	\$798.5	\$191.8	\$200.5	\$202.2	\$217.5	\$812.0	\$195.3	\$194.0	\$209.4	\$223.2	\$822.0	\$749.3
Selling, General & Administrative, GAAP	\$834.8	\$824.6	\$798.8	\$877.1	\$827.8	\$841.7	\$814.0	\$208.8	\$207.7	\$206.8	\$213.2	\$836.5	\$202.1	\$199.5	\$215.5	\$225.4	\$842.5	\$769.8
Research & Development Expense, Non-GAAP	\$198.2	\$196.7	\$227.9	\$247.6	\$256.7	\$254.8	\$281.8	\$60.2	\$60.8	\$70.2	\$72.0	\$263.2	\$84.1	\$83.0	\$75.1	\$68.9	\$311.1	\$300.4
Research & Development Expense, GAAP	\$199.2	\$202.7	\$217.8	\$260.6	\$256.9	\$247.4	\$295.9	\$73.5	\$60.5	\$71.3	\$75.3	\$280.6	\$91.1	\$95.1	\$100.2	\$73.3	\$359.6	\$360.5
Total Operating Expenses, Non-GAAP	\$1,004.6	\$992.9	\$1,004.4	\$1,082.1	\$1,062.1	\$1,069.5	\$1,080.3	\$252.0	\$261.3	\$272.4	\$289.5	\$1,075.2	\$279.5	\$277.0	\$284.5	\$292.1	\$1,133.1	\$1,049.7
Total Operating Expenses, GAAP	\$1,034.0	\$1,027.3	\$1,026.9	\$1,148.2	\$1,084.7	\$1,089.2	\$1,109.9	\$282.3	\$268.2	\$278.1	\$288.5	\$1,117.1	\$293.1	\$294.6	\$315.7	\$298.7	\$1,202.1	\$1,130.3
Adjusted EBITDA			\$546.4	\$711.1	\$667.9	\$635.9	\$479.5	\$113.7	\$124.0		\$110.4	\$348.1	\$80.7	\$101.6	\$94.9	\$110.3	\$387.5	\$289.5
Dividend from Sartorius AG			\$8.9	\$19.0	\$31.6	\$34.8	\$17.9	\$17.6	\$0.0		\$0.0	\$17.6	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
EBITDA	\$34.8	\$363.9	\$559.5	\$637.9	\$619.9	\$483.7	\$420.6	\$61.8	\$117.7	\$109.5	\$104.1	\$393.1	\$74.4	\$95.3	\$88.6	\$104.0	\$362.3	\$264.3
Depreciation & Amortization	\$138.1	\$134.2	\$138.1	\$137.6	\$137.3	\$145.9	\$151.6	\$38.1	\$40.6	\$44.2	\$36.4	\$159.3	\$34.2	\$35.2	\$40.7	\$38.1	\$148.2	\$137.1
Operating Income, Non-GAAP	\$244.1	\$278.5	\$426.6	\$582.1	\$524.0	\$378.9	\$331.3	\$63.0	\$88.6	\$77.0	\$83.4	\$312.0	\$72.4	\$79.6	\$87.7	\$83.9	\$323.6	\$283.8
Operating Income, GAAP	(\$103.3)	\$229.7	\$421.3	\$500.3	\$482.6	\$337.8	\$269.0	\$23.7	\$77.1	\$65.3	\$67.8	\$233.9	\$40.2	\$60.1	\$47.9	\$65.9	\$214.0	\$127.3
Interest Expense	\$24.0	\$23.4	\$21.9	\$1.6	\$38.1	\$49.4	\$48.9	\$12.0	\$12.6	\$12.3	\$9.2	\$46.1	\$9.8	\$11.5	\$12.8	\$11.7	\$45.7	\$43.1
Foreign Currency Exchange (Gains) Losses, Net	\$2.9	\$2.2	\$1.8	\$2.8	(\$0.2)	(\$7.3)	(\$3.9)	(\$2.7)	\$1.1	(\$2.9)	(\$2.9)	(\$7.4)	(\$2.9)	(\$2.9)	(\$2.9)	(\$2.9)	(\$11.6)	(\$11.6)
(Gains) Losses from Change in Fair Market Value of Equity Securities & Loan Receivable	(\$606.2)	(\$2,031.0)	(\$4,495.8)	(\$4,926.2)	\$5,193.6	\$1,252.3	\$2,656.8	(\$31.8)	(\$334.4)	\$495.3	\$0.0	\$129.1	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Other Expense (Income), Net, Non-GAAP	(\$28.1)	(\$27.9)	(\$14.5)	(\$33.7)	(\$68.5)	(\$107.5)	(\$94.9)	(\$35.7)	(\$16.9)	(\$15.3)	(\$16.9)	(\$84.8)	(\$36.5)	(\$14.5)	(\$16.7)	(\$19.0)	(\$86.7)	(\$83.5)
Other Expense (Income), Net, GAAP	(\$36.6)	(\$26.1)	(\$24.5)	(\$26.8)	(\$44.6)	(\$106.4)	(\$90.3)	(\$37.2)	(\$16.2)	(\$8.3)	(\$12.8)	(\$74.5)	(\$36.5)	(\$13.9)	(\$13.3)	(\$14.0)	(\$77.7)	(\$78.5)
Pre-Tax Income, Non-GAAP	\$245.4	\$280.7	\$417.5	\$611.4	\$554.6	\$444.3	\$381.2	\$89.4	\$91.8	\$82.9	\$94.0	\$358.1	\$102.0	\$85.6	\$94.5	\$94.1	\$376.2	\$335.8
Pre-Tax Income, GAAP	\$512.7	\$2,261.1	\$4,907.6	\$5,449.1	(\$4,704.3)	(\$850.1)	(\$2,342.5)	\$83.4	\$414.0	(\$431.1)	\$74.4	\$140.7	\$69.8	\$65.4	\$51.3	\$71.1	\$257.6	\$174.3
Income Tax, Non-GAAP	\$69.8	\$67.6	\$100.2	\$129.9	\$122.0	\$99.1	\$90.1	\$18.4	\$20.8	\$22.1	\$25.1	\$86.4	\$27.2	\$22.8	\$25.2	\$25.1	\$100.4	\$89.7
Income Tax, GAAP	\$147.0	\$502.4	\$1,103.8	\$1,194.8	(\$1,076.7)	(\$212.8)	(\$498.3)	\$19.4	\$96.2	(\$89.2)	\$15.4	\$41.8	\$14.4	\$13.5	\$10.6	\$14.7	\$53.3	\$36.1
Tax Rate, Non-GAAP	28.7%	24.1%	24.0%	21.2%	22.0%	22.3%	23.6%	20.6%	22.7%	26.7%	26.7%	24.1%	26.7%	26.7%	26.7%	26.7%	26.7%	26.7%
Tax Rate, GAAP	28.7%	22.2%	22.4%	21.9%	22.9%	25.0%	21.3%	23.3%	23.2%	20.7%	20.7%	29.7%	20.7%	20.7%	20.7%	20.7%	20.7%	20.7%
Net Income (Loss), Non-GAAP	\$175.6	\$213.1	\$317.2	\$481.6	\$432.6	\$345.2	\$291.1	\$71.0	\$71.0	\$60.8	\$68.9	\$271.7	\$74.8	\$62.7	\$69.3	\$69.0	\$275.8	\$246.1
Net Income (Loss), GAAP	\$365.6	\$1,758.7	\$3,814.2	\$4,254.3	(\$3,627.5)	(\$637.3)	(\$1,844.2)	\$64.0	\$317.8	(\$341.9)	\$59.0	\$98.9	\$55.3	\$51.8	\$40.7	\$56.4	\$204.2	\$138.2
Diluted Shares Outstanding, Non-GAAP	30.2	30.2	30.2	30.2	30.0	29.3	28.2	28.0	27.2	27.0	26.9	27.2	26.8	26.7	26.6	26.5	26.6	26.3
Diluted Shares Outstanding, GAAP	30.2	30.2	30.2	30.2	29.8	29.2	28.2	28.0	27.2	26.9	26.8	27.2	26.7	26.6	26.6	26.5	26.6	26.2
Diluted EPS, Non-GAAP	\$5.81	\$7.06	\$10.52	\$15.94	\$14.42	\$11.78	\$10.31	\$2.54	\$2.61	\$2.26	\$2.57	\$9.98	\$2.79	\$2.35	\$2.61	\$2.60	\$10.36	\$9.38
Diluted EPS, GAAP	\$12.10	\$58.27	\$126.47	\$140.83	(\$121.79)	(\$21.82)	(\$65.36)	\$2.29	\$11.67	(\$12.70)	\$2.20	\$3.46	\$2.07	\$1.95	\$1.53	\$2.13	\$7.68	\$5.27



---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	<b>D</b>
Growth Score	<b>B</b>
Momentum Score	<b>A</b>
VGM Score	<b>B</b>

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

## Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.